Talk to an expert. Get in touch.
© 2024 G&L Scientific
Found 75 results for Regulatory Affairs
G&L Insights: Autumn 22 edition
Assessing the value of eCTD baseline submissions
The benefits of Outsourcing
G&L honoured with Queen’s Award for Enterprise
Mental Health Week 2023: Why Exercise Matters
Mental Health Week 2023: Anxiety
Mental Health Week: The TikTok effect
The importance of a 'living' Regulatory Strategy
Mental Health Week: LGBT+ youth facing 'widespread mental health crises'
Mental Health Week: Protecting and maintaining mental health
Why regulatory consultancy makes sense
Clinical Trials - why the patient's voice matters
Understanding the role of the FDA in the importation of pharmaceutical products
Counting the health costs of lack of exercise
Alzheimer's Disease: why drug repurposing could be the answer
Why outsourcing is a worthwhile investment
Solutions start here
G&L: Proud advocates of inclusivity and diversity
Regulatory and competitor Insights - critical to success
The vital role of Pre-Exposure Prophylaxis in HIV prevention
WAAW - Day One: The growing concern of Antimicrobial Resistance
WAAW - Day Two: The risks of AMR
WAAW - Day Three: Practical steps to reduce AMR
WAAW - Day Four: Transforming EU legislation: A new era for veterinary medicinal products
WAAW - Day Five: Presentation by Doctor Sarah Hobson
TOPRA Symposium 2023: Perspectives on new EU regulatory legislation
TOPRA Symposium 2023: Big data and regulatory decision-making
TOPRA Symposium 2023: Patient engagement in medicines’ regulatory lifecycle
TOPRA Symposium 2023: Support and assistance for SMEs
Industry-leading NPS for G&L
G&L growth continues with two strategic appointments
MHRA introduces new procedures for Marketing Authorisation Applications
eCTD 4.0: The evolution of regulatory submissions
The Implementation of eCTD in Singapore
Ensuring submission readiness in eCTD publishing
eCTD 4.0: FDA Implementation Plans
Navigating the gene therapy landscape
Developing a fit-for-purpose and phase-appropriate Quality Management System
Healthcare transformation: Is digital technology the answer to productivity?
The impact of FDA’s Project Optimus and Project FrontRunner
Manufacturing site rationalization – a regulatory and logistical challenge
Understanding the Comparable Overseas Regulator (COR) report-based process
Understanding the impact of AI on Regulatory Affairs
Navigating post-Brexit drug regulation: The UK’s path forward amidst political change
G&L Leadership Reflections - Navigating biopharma transformation – Bill Griffiths
G&L Leadership Reflections - Organization design - Paul Kuiken
CEP 2.0 - changes at a glance
G&L Leadership Reflections - External Consultants - Paul Kuiken
Digital Technology Week: Introduction
Digital Technology Week: Debunking the myths of digital technology
Digital Technology Week: Digital technology adoption in pharmaceuticals as a precursor for regulatory affairs
Digital Technology Week: Digital technology potential in Regulatory Affairs
King’s Award success for G&L Healthcare Advisors
Dr. Steven Hildemann, MD, PhD, appointed as Non-Executive Director
Understanding the Union Product Database (UPD)
Regulatory expert appointed to lead West Coast US client engagement for G&L
G&L expands global reach and service offering with SmartStep Consulting acquisition
From complexity to cohesion: EAEU's role in CIS pharmaceutical regulations
G&L appoints Kevin Webb as Chief Growth Officer
G&L Healthcare Advisors to join esteemed panel at Biocom California event
Maximizing efficiency in pharmaceutical regulatory affairs with staff augmentation
Development, Regulatory & Market Access strategic alignment – missed opportunities?
From compliance to innovation – the key changes in pharmaceutical packaging regulations
G&L Healthcare Advisors to participate in Clinical Outsourcing Group Bay Area 2024
G&L Healthcare Advisors presented with King’s Award for Enterprise
World Antimicrobial Resistance Awareness Week: Educate, advocate, act now
Confronting Antimicrobial Resistance: current challenges and strategies
The One Health approach to combating AMR
Latest innovations in AMR diagnosis and mitigation
WHO guidance on tackling AMR
The importance of ALCOA++ principles in Pharmaceutical Regulatory Affairs
Updates and impacts: Understanding the EMA’s revised guideline on active substances
G&L commits to further strategic growth with key appointments
G&L welcomes Arun Luckychetty as Vice President, Global Head of Business Development
Navigating the EMA’s new fee structure: Strategies to cut costs and stay ahead
Write to us at hello@gandlscientific.com
+44 020 3143 2210
Send us a message on ourcontact form